title: Effect of a statin on an in vitro model of endometriosis.
abstract: OBJECTIVE
  To determine the inhibitory effect of a statin on angiogenesis in a three-dimensional (3-D) culture of human endometrial fragments in vitro. Angiogenesis has been proposed as an important mechanism in the pathogenesis of endometriosis, and statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) have been shown to have anti-inflammatory and anti-angiogenic activity.
  
  
  METHODS
  Experimental in vitro study of human endometrial biopsies and 3-D culture in fibrin matrix.
  
  
  METHODS
  Research laboratory at a university-affiliated infertility center.
  
  
  METHODS
  Forty-six normal ovulating women undergoing infertility treatment.
  
  
  METHODS
  Endometrial samples obtained from the fundus of the uterine cavity were minced, and the fragments were placed in a three-dimensional fibrin matrix culture system.
  
  
  METHODS
  Presence or absence of proliferation of stromal cells and invasion of the fibrin matrix, presence or absence of vessel sprouting, and immunohistochemical characterization of cellular components.
  
  
  RESULTS
  During the 1st week of culture, invasion of stromal cells into the fibrin matrix occurred in the control group and in some wells outgrowths were observed. After 2 weeks, endometrial glands were observed in the outgrowths at a distance from the main tissue and were growing in conjunction with new vessel formation until the end of culture period. A concentration-dependent effect of lovostatin was seen on cell growth and angiogenesis in the experimental groups. In the presence of 5 and 10 microM of statin, angiogenesis was abolished, and cell proliferation was inhibited. In the presence of 1 microM of lovastatin, angiogenesis was reduced, but cell proliferation was not affected.
  
  
  CONCLUSIONS
  The statins were shown to be effective in inhibiting the mechanisms of cell proliferation and angiogenesis in an experimental model for the development of endometriosis-like tissue.
authors.affiliation: Toronto Centre for Advanced Reproductive Technology, Department of Obstetrics and Gynecology, Division of Reproductive Sciences, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
authors.forename: Navid
authors.initials: N
authors.lastname: Esfandiari
authors.forename: Mozafar
authors.initials: M
authors.lastname: Khazaei
authors.forename: Jafar
authors.initials: J
authors.lastname: Ai
authors.forename: Ryszard
authors.initials: R
authors.lastname: Bielecki
authors.forename: Lynda
authors.initials: L
authors.lastname: Gotlieb
authors.forename: Edward
authors.initials: E
authors.lastname: Ryan
authors.forename: Robert F
authors.initials: RF
authors.lastname: Casper
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004715:Endometriosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D008148:Lovastatin / Q000008:administration & dosage*; D009389:Neovascularization, Pathologic / Q000150:complications / Q000473:pathology* / Q000517:prevention & control*
chemical_list: D020533:Angiogenesis Inhibitors; D008148:Lovastatin